{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:39Z","timestamp":1789545639388,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) patients are predominantly elderly with comorbidities that have an impact on patient mortality and treatment decisions. We previously reported the patient characteristics and overall survival outcomes of the Finnish MM cohort diagnosed between 2005 and 2016 in a nationwide retrospective registry study comprising 3,851 adults. Here, we report detailed comorbidity characteristics for this real-world Finnish MM population at cohort entry and during follow-up. Data on diagnoses and causes of death were obtained from Finnish healthcare data registries and interrogated using various multistate time-to-event models. In the year preceding MM diagnosis, comorbidities (as per Charlson Comorbidity Index definition) were recorded in 38.0% of the cohort, of which 27.9% presented with pre-existing cardiovascular disease (CVD) and 4.8% had suffered a major adverse cardiac event (MACE). At 2\u00a0years post-MM diagnosis, cumulative incidence for CVD and MACE more than doubled to 57.1% and 11.4%, respectively, and only 31.9% of the cohort remained CVD-free. Prevalent secondary malignancies were recorded in 16.8% of the patient population at MM diagnosis, with cumulative incidence increasing steadily to 27.5% at 2\u00a0years and 33% at 5\u00a0years post-diagnosis. The main cause of mortality attributed to MM, CVD, secondary malignancy, or other causes remained stable throughout the follow-up, at an average of 74.2%, 9.4%, 9.8%, and 6.5%, respectively. Prevalence of CVDs and secondary malignancies is high in Finnish patients at MM diagnosis, with older male patients suffering from higher MACE and mortality risk. Proper recording and management of comorbidities alongside novel treatments remain crucial for optimal MM management.<\/jats:p>","DOI":"10.1007\/s00277-022-04959-9","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T07:02:34Z","timestamp":1663052554000},"page":"2485-2495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005\u20132016"],"prefix":"10.1007","volume":"101","author":[{"given":"Iiro","family":"Toppila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kysenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatu","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann Ida","family":"Lassenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Lievonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"4959_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A et al (2018) Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 4:1221. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"4959_CR2","doi-asserted-by":"publisher","unstructured":"Ludwig H, Novis Durie S, Meckl A et al (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 15:6\u201325. https:\/\/doi.org\/10.1634\/theoncologist.2020-0141","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"4959_CR3","unstructured":"Finnish Cancer Registry (2022) https:\/\/tilastot.syoparekisteri.fi\/syovat, data from 2022-07-04, version 2022-08-16-001. Accessed 20 Mar 2022"},{"key":"4959_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M et al (2017) Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia 31:1915\u20131921. https:\/\/doi.org\/10.1038\/leu.2016.380","journal-title":"Leukemia"},{"key":"4959_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04481-4","author":"I Toppila","year":"2021","unstructured":"Toppila I, Miettinen T, Lassenius MI et al (2021) Characteristics and survival trends in Finnish multiple myeloma patients\u2014a nationwide real-world evidence study. Ann Hematol 100:1779\u20131787. https:\/\/doi.org\/10.1007\/s00277-021-04481-4","journal-title":"Ann Hematol"},{"key":"4959_CR6","doi-asserted-by":"publisher","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos M-V (2019) Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 9:26. https:\/\/doi.org\/10.1038\/s41408-019-0183-y","DOI":"10.1038\/s41408-019-0183-y"},{"key":"4959_CR7","doi-asserted-by":"publisher","unstructured":"Li W, Cornell RF, Lenihan D, et al (2016) Cardiovascular complications of novel multiple myeloma treatments. Circulation 133:908\u2013912. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018351","DOI":"10.1161\/CIRCULATIONAHA.115.018351"},{"key":"4959_CR8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C et al (2018) Cardiovascular adverse events in modern myeloma therapy \u2013 incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica 103:1422\u20131432. https:\/\/doi.org\/10.3324\/haematol.2018.191288","journal-title":"Haematologica"},{"key":"4959_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","volume":"20","author":"JL Dempsey","year":"2019","unstructured":"Dempsey JL, Johns A, Rosko AE, Lazarus HM (2019) The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 20:887\u2013902. https:\/\/doi.org\/10.1080\/14656566.2019.1577822","journal-title":"Expert Opin Pharmacother"},{"key":"4959_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101\u2013119. https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.007","journal-title":"Mayo Clin Proc"},{"key":"4959_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","volume":"121","author":"G Cook","year":"2018","unstructured":"Cook G, Zweegman S, Mateos M-V et al (2018) A question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma. Crit Rev Oncol Hematol 121:74\u201389. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.016","journal-title":"Crit Rev Oncol Hematol"},{"key":"4959_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A et al (2020) Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 20:8-17.e16. https:\/\/doi.org\/10.1016\/j.clml.2019.09.625","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4959_CR13","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"4959_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK et al (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15:333\u2013342. https:\/\/doi.org\/10.1016\/S1470-2045(13)70609-0","journal-title":"Lancet Oncol"},{"key":"4959_CR15","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1038\/bcj.2016.114","volume":"6","author":"JR Jones","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM et al (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J 6:e506. https:\/\/doi.org\/10.1038\/bcj.2016.114","journal-title":"Blood Cancer J"},{"key":"4959_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/annonc\/mdw606","volume":"28","author":"P Musto","year":"2017","unstructured":"Musto P, Anderson KC, Attal M et al (2017) Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 28:228\u2013245. https:\/\/doi.org\/10.1093\/annonc\/mdw606","journal-title":"Ann Oncol"},{"key":"4959_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cam4.1128","volume":"6","author":"H Gregersen","year":"2017","unstructured":"Gregersen H, Vangsted AJ, Abildgaard N et al (2017) The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med 6:1807\u20131816. https:\/\/doi.org\/10.1002\/cam4.1128","journal-title":"Cancer Med"},{"key":"4959_CR18","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.18632\/oncotarget.26872","volume":"10","author":"D Backs","year":"2019","unstructured":"Backs D, Saglam I, L\u00f6ffler C et al (2019) Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Oncotarget 10:3154\u20133165. https:\/\/doi.org\/10.18632\/oncotarget.26872","journal-title":"Oncotarget"},{"key":"4959_CR19","doi-asserted-by":"publisher","unstructured":"Rocchi S, Tacchetti P, Pantani L et al (2020) A real\u2010world efficacy and safety analysis of combined carfilzomib, lenalidomide and dexamethasone (KRD) in relapsed\/refractory multiple myeloma. Hematol Oncol:hon.2820. https:\/\/doi.org\/10.1002\/hon.2820","DOI":"10.1002\/hon.2820"},{"key":"4959_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A et al (2018) Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica 103:506\u2013513. https:\/\/doi.org\/10.3324\/haematol.2017.178103","journal-title":"Haematologica"},{"key":"4959_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jacc.2007.10.034","volume":"51","author":"KE Kip","year":"2008","unstructured":"Kip KE, Hollabaugh K, Marroquin OC, Williams DO (2008) The problem with composite end points in cardiovascular studies. J Am Coll Cardiol 51:701\u2013707. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.034","journal-title":"J Am Coll Cardiol"},{"key":"4959_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2288-11-83","volume":"11","author":"SK Thygesen","year":"2011","unstructured":"Thygesen SK, Christiansen CF, Christensen S et al (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83. https:\/\/doi.org\/10.1186\/1471-2288-11-83","journal-title":"BMC Med Res Methodol"},{"key":"4959_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"4959_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W et al (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416\u2013429. https:\/\/doi.org\/10.1111\/ejh.12790","journal-title":"Eur J Haematol"},{"key":"4959_CR25","doi-asserted-by":"publisher","unstructured":"Coluzzi F, Rolke R, Mercadante S (2019) Pain management in patients with multiple myeloma: an update. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11122037","DOI":"10.3390\/cancers11122037"},{"key":"4959_CR26","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1097\/MLR.0b013e318297429c","volume":"53","author":"SR Austin","year":"2015","unstructured":"Austin SR, Wong Y-N, Uzzo RG et al (2015) Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72. https:\/\/doi.org\/10.1097\/MLR.0b013e318297429c","journal-title":"Med Care"},{"key":"4959_CR27","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P et al (2016) Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 37:3232\u20133245. https:\/\/doi.org\/10.1093\/eurheartj\/ehw334","journal-title":"Eur Heart J"},{"key":"4959_CR28","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2468-2667(19)30224-5","volume":"4","author":"AK Knudsen","year":"2019","unstructured":"Knudsen AK, Allebeck P, Toll\u00e5nes MC et al (2019) Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet Public Health 4:e658\u2013e669. https:\/\/doi.org\/10.1016\/S2468-2667(19)30224-5","journal-title":"Lancet Public Health"},{"key":"4959_CR29","unstructured":"Pajunen A Statistics Finland - 2. Ischaemic heart disease mortality decreased further. https:\/\/www.stat.fi\/til\/ksyyt\/2016\/ksyyt_2016_2017-12-29_kat_002_en.html. Accessed 3 Feb 2021"},{"key":"4959_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12185-018-2538-8","volume":"109","author":"S Yamasaki","year":"2019","unstructured":"Yamasaki S, Yoshimoto G, Kohno K et al (2019) Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. Int J Hematol 109:98\u2013106. https:\/\/doi.org\/10.1007\/s12185-018-2538-8","journal-title":"Int J Hematol"},{"key":"4959_CR31","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"4959_CR32","doi-asserted-by":"publisher","first-page":"afab211","DOI":"10.1093\/ageing\/afab211","volume":"51","author":"Y Yao","year":"2022","unstructured":"Yao Y, Sui W-W, Liao A-J et al (2022) Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age Ageing 51:afab211. https:\/\/doi.org\/10.1093\/ageing\/afab211","journal-title":"Age Ageing"},{"key":"4959_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.eurger.2016.06.006","volume":"7","author":"H Kerminen","year":"2016","unstructured":"Kerminen H, J\u00e4msen E, J\u00e4ntti P et al (2016) How Finnish geriatricians perform comprehensive geriatric assessment in clinical practice? Eur Geriatr Med 7:454\u2013458. https:\/\/doi.org\/10.1016\/j.eurger.2016.06.006","journal-title":"Eur Geriatr Med"},{"key":"4959_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41375-018-0272-0","volume":"33","author":"TW Klausen","year":"2019","unstructured":"Klausen TW, Gregersen H, Abildgaard N et al (2019) The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia 33:546\u2013549. https:\/\/doi.org\/10.1038\/s41375-018-0272-0","journal-title":"Leukemia"},{"key":"4959_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/10428194.2016.1207763","volume":"58","author":"DE Rollison","year":"2017","unstructured":"Rollison DE, Komrokji R, Lee J-H et al (2017) Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma 58:560\u2013568. https:\/\/doi.org\/10.1080\/10428194.2016.1207763","journal-title":"Leuk Lymphoma"},{"key":"4959_CR36","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung S-H, Richardson PG et al (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431\u2013e442. https:\/\/doi.org\/10.1016\/S2352-3026(17)30140-0","journal-title":"Lancet Haematol"},{"key":"4959_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamadermatol.2015.121","volume":"151","author":"JL DePry","year":"2015","unstructured":"DePry JL, Vyas R, Lazarus HM et al (2015) Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: a systematic review. JAMA Dermatol 151:775. https:\/\/doi.org\/10.1001\/jamadermatol.2015.121","journal-title":"JAMA Dermatol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04959-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T01:06:00Z","timestamp":1665104760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04959-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4959"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04959-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by each registered holder.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"KK, IT, MIL, and TM are employees of Medaffcon Oy; TM is an\u00a0employee of Takeda Finland; JL has received consultation fees from Amgen, Celgene, Bristol-Myers Squibb, Sanofi, Takeda, Janssen, and travel grants from Janssen, Celgene, Amgen, Novartis, TEVA, Takeda, Roche, Abbvie, Pfizer; PA has been the Hematologist in charge for treatment of plasma cell malignancies at the Helsinki University Hospital and has received consultation fees from Amgen, BMS, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda, and travel grants from AbbVie, Amgen, BMS, Celgene, Sanofi Genzyme, Janssen, Mundipharma, Novartis, Roche, and Teva.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}